Prima BioMed has an agreement with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany, to produce Prima’s CVac cancer immunotherapy product for the European clinical trials.
Prima BioMed has an agreement with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany, to produce Prima’s CVac cancer immunotherapy product for the European clinical trials. Preparation for production of CVac for the European trial has already started, and Prima and the Fraunhofer IZI are working together to prepare the facility to support CVac clinical trials in Europe in early 2011.
